A.O.Ospedali Riuniti Papardo Piemonte U.O.C. di Oncologia Medica
Welcome,         Profile    Billing    Logout  
 6 Trials 
8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Adamo, Vincenzo
BEAT, NCT03896074 / 2018-003973-82: Atezolizumab Versus Atezolizumab Plus Bevacizumab as First Line in NSCLC Patients

Not yet recruiting
2
206
Europe
Atezolizumab, Bevacizumab
Fondazione Ricerca Traslazionale
Non-small-cell Lung Cancer Patients
05/22
04/23
MP-LALC, NCT03379441: Pembrolizumab (MK-3475) as Maintainance in Treated Patients With Unresectable Stage III NSCLC

Not yet recruiting
2
126
Europe
Pembrolizumab Injectable Product
University of Turin, Italy
Non Small Cell Lung Cancer Patients
01/23
01/23
GIM24-PALBO-BP, NCT04318223 / 2019-000221-45: Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal Therapy

Recruiting
2
168
Europe
Palbociclib
Consorzio Oncotech
Metastatic Breast Cancer, Locally Advanced Breast Cancer
07/23
07/23
COMBI-TED, NCT04884282 / 2020-005170-10: Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)

Recruiting
2
105
Europe
Tedopi, Nivolumab, Docetaxel
Fondazione Ricerca Traslazionale, Bristol Myer Squibb International Corporation, OSE Immunotherapeutics
Metastatic Non Small Cell Lung Cancer
10/23
05/25
ROME, NCT04591431 / 2018-002190-21: The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy

Active, not recruiting
2
400
Europe
Erlotinib, Trastuzumab, Trastuzumab emtansine, Pertuzumab, Lapatinib, Everolimus, Vemurafenib, Cobimetinib, Alectinib, Brigatinib, Palbociclib, Ponatinib, Vismogedib, Itacitinib, Ipatasertib, Entrectinib, Atezolizumab, Nivolumab, Ipilimumab, Pemigatinib, Oncology Drugs, Pralsetinib, Selpercatinib, Talazoparib, Tepotinib, Alpelisib
Fondazione per la Medicina Personalizzata
Breast Cancer, Gastrointestinal Cancer, Non Small Cell Lung Cancer, Other Cancer
12/24
06/25
NCT04416672: Validation of the Italian Version of the PRO-CTCAE

Recruiting
N/A
3675
Europe
PRO-CTCAE items
National Cancer Institute, Naples
Malignant Neoplasms
07/24
07/24
IDENTITY, NCT05835739: InheriteD brEast caNcer iTalian regIsTrY A Retrospective-prospective Observational Cohort Study to Evaluate Cancer Prevention Strategies in Women With a Deleterious Mutation in BRCA1-2

Recruiting
N/A
78
Europe
Centro di Riferimento Oncologico - Aviano
Breast Cancer
09/25
09/35
RATIONAL, NCT05918666: National Register of Actionable Mutations

Recruiting
N/A
3000
Europe
Federation of Italian Cooperative Oncology Groups, Roche Pharma AG, AstraZeneca, Bayer, Bristol-Myers Squibb, Janssen, LP, Takeda, Amgen, Daiichi Sankyo, Inc., Eli Lilly and Company, Novartis, Clinical Research Technology S.r.l.
Solid Tumours in Advanced Stages
10/26
10/26

Download Options